Jan 29 (Reuters) - Strides Pharma Science Ltd SRID.NS :
* DEC QUARTER CONSOL NET PROFIT 2.93 BILLION RUPEES VERSUS PROFIT OF 854.8 MILLION RUPEES LAST YEAR
* CONSENSUS FORECAST FOR DEC QUARTER CONSOL NET PROFIT WAS 285.5 MILLION RUPEES
* DEC QUARTER CONSOL REVENUE FROM OPERATIONS 7.95 BILLION RUPEES VERSUS 7.49 BILLION RUPEES LAST YEAR
* IN DEC QTR, CO HAD A GAIN OF 2.72 BLN RUPEES ON DISPOSAL OF ASSETS
* SAYS STRIDES TO EXIT ARROW FOR A VALUE OF A$394 MILLION
* SAYS ACQUISITION OF 80 PERCENT STAKE IN PHARMAPAR INC TO BUILD OUT CANADIAN OPERATIONS
* ACQUISITION OF 100 PERCENT STAKE IN VENSUN PHARMACEUTICALS, INC. TO TAKE CONTROL OF THE PARTNERED PRODUCTS
* TO CONVERT CO'S 50:50 JVS WITH VIVIMED TO 100% OWNERSHIP
* CO TO SELL COMPLETE STAKE IN ARROW TO ENTITIES OWNED AND OPERATED BY DENNIS BASTAS, EXECUTIVE CHAIRMAN AND CO-FOUNDER OF ARROW
* ARROW WILL MERGE WITH APOTEX TO CREATE THE NEW ENTITY ARROTEX
* PROPOSED TRANSACTION ALLOWS STRIDES TO ENTER INTO A 10-YEAR PREFERRED SUPPLIER CONTRACT WITH THE MERGED ENTITY
* TRANSACTION TO EXIT ARROW WOULD BE IMMEDIATELY EPS ACCRETIVE
* WILL ALSO RETAIN ACCESS TO IP OF 140 PRODUCTS IN ARROW PORTFOLIO WITH FUNGIBILITY IN OTHER GLOBAL MARKETS